Research indicates the Pfizer-BioNTech vaccine effectively reduces MIS-C incidence in children, supporting vaccination as a critical public health measure.
Pfizer-BioNTech vaccine provides strong protection against MIS-C in children aged 5–17
- Post author:
- Post published:November 12, 2024
- Post category:uncategorized